Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows positive financial performance with increased revenue and EPS guidance, strong product development, and a robust shareholder return plan. The Q&A section indicates management's optimism about future growth, particularly in biopharma and AI integration, despite cautious spending in some sectors. The raised guidance and positive sentiment in key areas suggest a likely positive impact on the stock price over the next two weeks.
Key Financial Performance
Q4 Revenue Revenue grew 7% year-over-year to $12.21 billion. The growth was driven by strong execution, proven growth strategy, and operational performance.
Q4 Adjusted Operating Income Adjusted operating income grew 6% to $2.88 billion. This was supported by productivity and volume leverage, though partially offset by unfavorable mix and FX headwinds.
Q4 Adjusted Operating Margin Adjusted operating margin was 23.6%, 30 basis points lower than Q4 last year, impacted by over 100 basis points of headwind from tariffs and related FX.
Q4 Adjusted EPS Adjusted EPS grew 8% to $6.57 per share. This was driven by strong operational performance, though partially offset by FX headwinds.
Full Year 2025 Revenue Revenue grew 4% to $44.56 billion. Growth was supported by broad-based performance across bioproduction, research and safety market channel, and other segments.
Full Year 2025 Adjusted Operating Income Adjusted operating income grew 4% to $10.11 billion. This was achieved despite macroeconomic headwinds, including tariffs and FX.
Full Year 2025 Adjusted Operating Margin Adjusted operating margin was 22.7%, 10 basis points higher than the prior year, despite over 100 basis points of headwind from tariffs and FX.
Full Year 2025 Adjusted EPS Adjusted EPS grew 5% to $22.87 per share. This reflects strong operational performance and active management of the business.
Pharma and Biotech Q4 Growth High single-digit growth in Q4, driven by strong bioproduction business and research and safety market channel.
Pharma and Biotech Full Year Growth Mid-single-digit growth for the full year, supported by bioproduction, research and safety market channel, and analytical instruments.
Academic and Government Q4 and Full Year Performance Declined in the low single digits during both the quarter and the full year, impacted by macro conditions in the U.S. and China.
Industrial and Applied Q4 and Full Year Performance Declined in the low single digits during the quarter but grew in the low single digits for the full year, with strong performance in research and safety market channel and electron microscopy.
Diagnostics and Healthcare Q4 Growth Low single-digit growth in Q4, driven by Specialty Diagnostics businesses.
Diagnostics and Healthcare Full Year Growth Flat growth for the full year, with strong contributions from transplant diagnostics and immunodiagnostics businesses.
Life Science Solutions Q4 Revenue Reported revenue increased 13% year-over-year, with organic revenue growth of 4%, led by bioproduction business.
Life Science Solutions Full Year Revenue Reported revenue increased 8%, with organic revenue growth of 3%, driven by bioproduction.
Analytical Instruments Q4 Revenue Reported revenue increased 1%, with flat organic revenue growth, led by chromatography and mass spectrometry.
Analytical Instruments Full Year Revenue Reported revenue increased 1%, with flat organic revenue growth.
Specialty Diagnostics Q4 Revenue Reported revenue grew 5%, with organic revenue growth of 3%, led by clinical diagnostics, transplant diagnostics, and immunodiagnostics.
Specialty Diagnostics Full Year Revenue Reported revenue increased 4%, with organic revenue growth of 2%.
Laboratory Products and Biopharma Services Q4 Revenue Reported revenue increased 7%, with organic revenue growth of 5%, driven by research and safety market channel and pharma services.
Laboratory Products and Biopharma Services Full Year Revenue Reported revenue grew 4%, with organic revenue growth of 3%.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Thermo Scientific Orbitrap Astral Zoom: Launched to deliver greater sensitivity, speed, and depth of coverage in mass spectrometry, enabling researchers to uncover new biological insights and advance precision medicine.
Thermo Scientific 5-liter DynaDrive single-use bioreactor: Expanded single-use portfolio to increase workflow efficiencies and scale up manufacturing of new therapies for pharma and biotech customers.
Thermo Scientific Krios 5 Cryo-TEM: Advances structural biology by enabling faster, higher-resolution insights to support drug discovery and development.
Thermo Scientific Helios MX1 plasma-focused ion beam SEM: A fully automated semiconductor analysis system designed to accelerate time to data for yield ramp and fab process control.
Ion Torrent Oncomine Dx Target Test: Received FDA approval as a companion diagnostic for Bayer's new therapy for non-small cell lung cancer.
EXENT System: Achieved U.S. 510(k) clearance as an automated platform for earlier and more confident diagnosis of multiple myeloma and related disorders.
Expansion of bioprocess design centers in Asia: Opened a new site in India to better support customers in the region.
Acquisition of Clario: Announced a definitive agreement to acquire Clario, a leader in digital endpoint data solutions for clinical trials, expected to close by mid-2026.
PPI Business System: Enabled cost management, operational excellence, and strong earnings growth while embedding artificial intelligence to enhance efficiency.
Capital deployment: Deployed $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders through stock buybacks and dividends.
Strategic collaboration with OpenAI: Aimed at increasing the use of artificial intelligence to improve productivity and embed AI capabilities in products and services.
Technology alliance with Chan Zuckerberg Institute: Focused on developing new technologies for advanced biological imaging to better visualize human cells.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macro Conditions Impacting Academic and Government Markets: Performance in the academic and government end market was impacted by macroeconomic conditions in the U.S. and China, leading to a decline in revenue in the low single digits for both the quarter and the full year.
Tariffs and U.S. Policy Dynamics: The company faced challenges related to tariffs and U.S. policy dynamics, which required active management to mitigate their impact on financial performance.
Foreign Exchange Volatility: Continued volatility in foreign exchange rates, driven by trade tensions, created headwinds, including a 65 basis point impact on margins in Q4.
China Market Decline: Revenue in China declined in the low single digits for the quarter and mid-single digits for the full year, reflecting challenges in this key market.
Integration and Investment Phase of Acquisitions: The integration and investment phase of recent acquisitions, such as the filtration and separation business and Clario, is expected to create short-term financial headwinds, including a 20 basis point impact on adjusted operating margins in 2026.
Pharma Services Revenue Phasing: The expected phasing of revenue in the Pharma Services business over the course of 2026 is anticipated to result in lower organic revenue growth in Q1 compared to the full year.
Tariff and FX Headwinds on Analytical Instruments: The Analytical Instruments segment experienced a 420 basis point decline in adjusted operating margin in Q4, primarily due to tariffs and related foreign exchange impacts.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: Thermo Fisher Scientific is initiating a 2026 revenue guidance range of $46.3 billion to $47.2 billion, representing 4% to 6% reported revenue growth over 2025. This includes 3% to 4% organic growth.
2026 Adjusted EPS Guidance: The company is projecting an adjusted EPS range of $24.22 to $24.80 per share, reflecting 6% to 8% growth in adjusted earnings per share.
Clario Acquisition Impact: The pending acquisition of Clario, expected to close by mid-2026, is projected to contribute $0.20 to $0.25 of incremental adjusted EPS for the year, representing an additional 1% growth in adjusted EPS.
Capital Expenditures: Net capital expenditures for 2026 are expected to range between $1.8 billion and $2 billion, driven by investments in U.S. manufacturing.
Free Cash Flow: Free cash flow for 2026 is projected to be in the range of $6.8 billion to $7.3 billion.
Adjusted Operating Margin Expansion: The company anticipates 50 basis points of adjusted operating margin expansion in 2026.
Q1 2026 Organic Revenue Growth: Organic revenue growth in Q1 2026 is expected to be a couple of points lower than the full-year guidance due to selling days and revenue phasing in the Pharma Services business.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: In 2025, Thermo Fisher Scientific returned approximately $600 million to shareholders through dividends.
Share Buybacks: In 2025, Thermo Fisher Scientific returned $3 billion to shareholders through stock buybacks.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives you confidence in the reacceleration from 2% organic growth in 2025 to 3%-4%?
A:Marc Casper explained that the guidance assumes market conditions similar to 2025, with an expectation of improvement over time due to the absence of negatives. He expressed optimism based on customer meetings in January but emphasized setting realistic expectations for the year.
Q:Is the framework of 3%-6% growth for 2026 and 2027 still intact?
A:Stephen Williamson confirmed that the framework remains consistent with prior assumptions, and Marc Casper added that the company is focused on delivering great earnings growth, with 6%-8% EPS growth expected without capital deployment.
Q:What is the sentiment on biopharma spending and 2026 pharma budgets?
A:Marc Casper noted positive sentiment in pharma, with confidence in navigating government agreements and excitement around pipelines. Biotech funding is improving, though there is a lag between funding flows and spending. January sentiment was positive, and the company is well-positioned as a trusted partner.
Q:Is mid-single-digit growth in biopharma for 2025 a reasonable expectation?
A:Stephen Williamson agreed that mid-single-digit growth is a reasonable way to frame the year, contributing to the overall 3%-4% growth guidance.
Q:How are industry supply-demand dynamics in Pharma Services entering 2026?
A:Marc Casper highlighted strong execution in Pharma Services, with high demand for sterile fill-finish and clinical trials logistics. The acquisition of the Sanofi site in New Jersey is expected to expand capacity and meet reshoring needs, contributing to long-term growth.
Q:What is the competitive position of the channel business?
A:Marc Casper stated that the channel business has performed well, with broad-based strength in pharma, biotech, and industrial customers. The company has maintained stable share in the academic and government sectors despite market pressures.
Q:How are ecosystem changes affecting customer preferences for outsourcing and the Accelerator offering?
A:Marc Casper explained that the Accelerator offering, launched in late 2024, focuses on reducing time and cost in drug development. It has resulted in meaningful contract wins. The company is also collaborating with OpenAI to further improve efficiency in clinical research.
Q:What is the impact of AI on wet lab research and demand for instruments?
A:Marc Casper noted a recovery in early research demand and stated that AI is being used to better link wet lab and data management. He expressed optimism that AI will lead to more confident and efficient research, driving demand for wet lab experimentation.
Q:How did Analytical Instruments perform in 4Q, and what are the expectations for 2026?
A:Marc Casper reported flat growth in 4Q due to headwinds in academic/government funding and China. The company performed well in pharma and biotech, driven by innovation. For 2026, the assumption is similar conditions to 2025, with cautious spending in academic/government sectors.
Q:What are the expectations for U.S. academic and government growth in 2026?
A:Marc Casper stated that the guidance assumes similar conditions to 2025, with cautious spending expected to abate later in the year. A flat to slightly up NIH budget is anticipated, which could create tailwinds over the next couple of years.
Q:What is the organic growth assumption for 2026 and 1Q?
A:Stephen Williamson indicated an assumption of 3% organic growth for 2026 and around 1% for the first quarter.
Q:What are the expectations for biopharma spending in 2026?
A:Marc Casper stated that the guidance assumes no change in market conditions, with potential for improvement as biotech funding flows. The company aims to deliver 6%-8% EPS growth and is optimistic about Clario's contribution.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of increased spending in the U.S. academic and government sectors, stating only that cautious spending is expected to abate later in the year. Additionally, while they expressed optimism about biopharma and biotech funding, they did not provide concrete data or timelines for when this would translate into increased spending.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Astral Zoom
CFO year
PPI System
RD
acquisition filtration
addition
agility
bioproduction research
breakthrough
cell
congratulation
culture
digit bioproduction
endpoint
exchange income
filtration separation
highlight
intelligence
leverage mix
market leader
partnership
passion
pharma service
point Laboratory
point basis
point headwind
power PPI
research business
separation Solventum
service business
service research
spectrometry
sustainability
tailwind
tariff FX
term position
transaction middle
volume leverage
word
TMO Transcript
Thermo Fisher Scientific Inc. (TMO) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-3
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Positive1-29
The earnings call summary shows positive financial performance with increased revenue and EPS guidance, strong product development, and a robust shareholder return plan. The Q&A section indicates management's optimism about future growth, particularly in biopharma and AI integration, despite cautious spending in some sectors. The raised guidance and positive sentiment in key areas suggest a likely positive impact on the stock price over the next two weeks.
Thermo Fisher Scientific Inc. (TMO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Thermo Fisher Scientific Inc. (TMO) Q3 2025 Earnings Call Transcript
Positive10-22
Thermo Fisher's earnings call highlights strong financial performance, with increased revenue and EPS guidance for 2025 and expected organic growth acceleration in 2026-2027. Strategic M&A, cost management, and improved tariff situations are positive factors. The Q&A session reinforced confidence in growth, despite challenges in China. The overall sentiment is positive due to optimistic guidance and strategic initiatives, suggesting a likely stock price increase in the coming weeks.
TMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
